title: Beneficial effects of montelukast against methotrexate-induced liver toxicity: a biochemical and histological study.
abstract: The effects of montelukast against methotrexate-induced liver damage were investigated. 35 Wistar albino female rats were divided into 5 groups as follows: group I: control; group II: montelukast (ML); group III: methotrexate (Mtx); group IV: montelukast treatment after methotrexate application (Mtx + ML); group V: montelukast treatment before methotrexate application (ML + Mtx). At the end of the experiment, the liver tissues of rats were removed. Malondialdehyde (MDA), myeloperoxidase (MPO), and reduced glutathione levels were determined from liver tissues. In addition, the liver tissues were examined histologically. MDA and MPO levels of Mtx group were significantly increased when compared to control group. In Mtx + ML group, these parameters were decreased as compared to Mtx group. Mtx injection exhibited major histological alterations such as eosinophilic staining and swelling of hepatocytes. The glycogen storage in hepatocytes was observed as decreased by periodic acid schiff staining in Mtx group as compared to controls. ML treatment did not completely ameliorate the lesions and milder degenerative alterations as loss of the glycogen content was still present. It was showed that montelukast treatment after methotrexate application could reduce methotrexate-induced experimental liver damage.
authors.affiliation: Department of Anatomy, School of Medicine, İnonu University Medical Faculty, 44280 Malatya, Turkey. evren.kose@inonu.edu.tr
authors.forename: Evren
authors.initials: E
authors.lastname: Kose
authors.forename: Hilal Irmak
authors.initials: HI
authors.lastname: Sapmaz
authors.forename: Ediz
authors.initials: E
authors.lastname: Sarihan
authors.forename: Nigar
authors.initials: N
authors.lastname: Vardi
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Turkoz
authors.forename: Nihat
authors.initials: N
authors.lastname: Ekinci
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003521:Cyclopropanes; D004353:Drug Evaluation, Preclinical; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008315:Malondialdehyde / Q000378:metabolism; D008727:Methotrexate / Q000633:toxicity*; D018384:Oxidative Stress; D010503:Periodic Acid-Schiff Reaction; D009195:Peroxidase / Q000378:metabolism; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D008315:Malondialdehyde; D006003:Glycogen; D009195:Peroxidase; D005978:Glutathione; C093875:montelukast; D008727:Methotrexate